Labiotech.eu

News and Trends 1 Oct 2015

Artificially Intelligent ‘Betsy’ will analyse 100,000 genomes for UK Government

The “Berg Interrogative Biology” program from Boston (US) is a form of artificial intelligence the UK government has employed to work its Genome project. The platform will use a combination of systems biology techniques to analyse up to 100,000 genomes sourced from England’s National Health Service (NHS) for Genomics England (owned by the UK Department […]

October 1, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 1 Oct 2015

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

Paris based Sofinnova continues to invest in the Alzheimer’s fight, with a €27.5M pot given to Swiss Asceneuron (originally a spin-off from Merck-Serono). Sofinnova therefore joins other investors such as JJDC in the new and optimistic biotech wave of therapies for neurodegenerative diseases like Alzheimer’s and progressive supranuclear palsy (PSP). The last decade has been fairly […]

October 1, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 1 Oct 2015

New record: 20 000 people visited us in September!

Hi there, After celebrating our first year, what could be a better news for the beginning of the second year than breaking a new record of traffic?! You were almost 20 000 (19 917 to be precise) different people visiting us during the month of September. That’s fairly awesome!! Thank you for being so many […]

October 1, 2015 - 1 minutemin - By Philip Hemme

News and Trends 1 Oct 2015

Neil Woodford’s Latest €25M UK Biotech pay-out is to AMO Pharma

As we already well know, Neil Woodford is an Economist investor listed as one of the most influential figures in the European biotech industry. From London (UK), his private equity firm Woodford Patient Capital Trust is now planning to dish out €25M to AMO Pharma, to further their phase II pipeline therapies for CNS disorders such […]

October 1, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 30 Sep 2015

CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?

CRISPR is already revolutionizing Biotechnology. However, like every biotech revolution, there then follows a patent war. But the discovery of a new gene editing protein (Cpf1), with the potential of replacing Cas9, could change this status-quo. As Business Insider puts its, CRISPR is “the biggest biotech discovery of the century“. And its true, it really changed […]

September 30, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 30 Sep 2015

Apitope relocates to Wales after €12M series B financing round

Now, as we’ve recently discussed here at Labiotech, there doesn’t appear to be many Welsh biotechs…however, this is all about to change, with major Autoimmune disease focused Apitope relocating it’s HQ to Wales. This is following a €12M series B fundraiser led by the Wales Lifesciences Fund for its monoclonal antibody pipeline. Aptiope are currently […]

September 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 30 Sep 2015

Gecko’s Heart surgery glue the new Cover of Science’s Translational Medicine

Gecko Biomedical is a young Parisian biotech which is now featured on the front cover of the Science Journal for Translational Medicine. We explore their surgery adhesive tech inspired by natural stickiness of molluscan slugs, and their latest proof of its application in heart surgery. Gecko Biomedical was only founded in 2013 by a rockstar […]

September 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 29 Sep 2015

Could an Alpaca’s monoclonal antibodies be used to treat an ultra-rare blood disease?

Ablynx‘s Nanobody platform has used the smaller than human monoclonal antibodies from an alpaca to develop the phase III Orphan designated drug Caplacizumab. A phase III study ‘Hercules’ is now pioneering Caplacizumab as the first ever anti-Von Willebrand factor (vWF) nanobody for treating an ultra-rare blood clotting disorder. Caplacizumab is a pioneering monoclonal antibody (mAb) […]

September 29, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 29 Sep 2015

A Cartridge system to revolutionize diagnosis time of infective pathogens?

Canada’s Axela partners up with Swiss Hutman Diagnostics to test the cartridge based detection kit with their pan-European infectious disease resources. The Alena System could revolutionize time and cost of diagnosing bacterial pathogens in meningitis, endocarditis and hospital-acquired infections etc. Hutman Diagnostics is originally from Basel (Switzerland) having been founded in 2011 as a developer […]

September 29, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 29 Sep 2015

Will Roche lose its Worldwide Leading position in Cancer treatments?

Roche is the worldwide leader in cancer treatments, but it’s threatened by the increasing competition of biosimilars and the development of next-generation cancer drugs. Is there a risk for the “biggest Biotechnology company worldwide” to lose its leading position on the lucrative anti-cancer business? The Swiss giant makes massive amount of cash with its cancer treatments, […]

September 29, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 28 Sep 2015

Sanofi and Regeneron’s Praluent succeeds at final hurdle with EU authorisation

Regeneron (NY, USA) has finally brought alirocumab (trade name Praluent) to the finish line with collaborator Sanofi, today announcing that the European commission has granted its hypercholesterolemia drug a marketing license for the EU. Having already been approved by the FDA in July, this completes Praluent’s launch into the Western pharma market. New-York based Regeneron […]

September 28, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 28 Sep 2015

Bio-mining the Diversity of Deserts: A Biotech industry Goldmine

Deserts can be either hot or cold according to their geographical location, leading to the evolution of extremophilic organisms which are adapted to withstand such hostile living conditions. Here, we explore some of the potential industrial biotech applications of desert microbes, from bioremediation of pollutants such as PCP, to the investigation of novel anti-cancer compounds. […]

September 28, 2015 - 3 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Artificially Intelligent ‘Betsy’ will analyse 100,000 genomes for UK Government

Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

New record: 20 000 people visited us in September!

Neil Woodford’s Latest €25M UK Biotech pay-out is to AMO Pharma

CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?

Apitope relocates to Wales after €12M series B financing round

Gecko’s Heart surgery glue the new Cover of Science’s Translational Medicine

Could an Alpaca’s monoclonal antibodies be used to treat an ultra-rare blood disease?

A Cartridge system to revolutionize diagnosis time of infective pathogens?

Will Roche lose its Worldwide Leading position in Cancer treatments?

Sanofi and Regeneron’s Praluent succeeds at final hurdle with EU authorisation

Bio-mining the Diversity of Deserts: A Biotech industry Goldmine

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!